Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders

Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: Are we still prescribing them without valid indications? Australas Med J 7, 465–470, 2014.10.4066/AMJ.2014.2093 Search in Google Scholar

Alosaimi FD, Fallata EO, Abalhassan M, Alhabbad A, Alzain N, Alhaddad B, Alassiry MZ. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract 22, 274–281, 2018.10.1080/13651501.2018.1425459 Search in Google Scholar

Amoros JG. Disfuncion erectil e inhibidores de la bomba de protones. Med Clin 114, 478–478, 2000.10.1016/S0025-7753(00)71336-4 Search in Google Scholar

Bahamondes L, Faundes A, Tambascia M, Trevisan M, Dachs JN, Pinotti JA. Menstrual pattern and ovarian function in women with hyperprolactinemia. Int J Gynaecol Obstet 23, 31–36, 1985.10.1016/0020-7292(85)90007-4 Search in Google Scholar

Ben-Jonathan N. Hypothalamic control of prolactin synthesis and secretion. In Prolactin (Ed. Horseman ND), Springer US, 1–24, 2001.10.1007/978-1-4615-1683-5_1 Search in Google Scholar

Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: Regulation and functions. Adv Exp Med Biol 846, 1–35, 2015.10.1007/978-3-319-12114-7_125472532 Search in Google Scholar

Bennett M. Vitamin B12 deficiency, infertility and recurrent fetal loss. J Reprod Med 46, 209–212, 2001. Search in Google Scholar

Biller BM. Hyperprolactinemia. Int Fertil Womens Med 44, 74–77, 1999. Search in Google Scholar

Biswas S, Rodeck C. Plasma prolactin levels during pregnancy. BJOG: Int J Obstet Gynaecol 83, 683–687, 1976.10.1111/j.1471-0528.1976.tb00913.x974045 Search in Google Scholar

Boyd AE, Reichlin S, Turksoy RN. Galactorrhea-amenorrhea syndrome: Diagnosis and therapy. Ann Int Med 87, 165–175, 1977.10.7326/0003-4819-87-2-165407824 Search in Google Scholar

Bravo ML, Pinto MP, Gonzalez I, Oliva B, Kato S, Cuello MA, Lange CA, Owen GI. Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine 48, 309–320, 2015.10.1007/s12020-014-0288-924853881 Search in Google Scholar

Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care, 9, 1–6, 2004. Search in Google Scholar

Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? Ann Clin Biochem 47, 292–300, 2010.10.1258/acb.2010.01002520592331 Search in Google Scholar

Butelman ER, Kreek MJ. κ-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like receptor agonists. Eur J Pharmacol 423, 243–249, 2001.10.1016/S0014-2999(01)01121-9 Search in Google Scholar

Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie JC, Racadot A, Fossati P. Hyperprolactinemia and sexual function in men. Horm Res 22, 196–203, 1985.10.1159/000180094 Search in Google Scholar

Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: Pathophysiology and therapeutic approach. Gynecol Endocrinol 31, 506–510, 2015.10.3109/09513590.2015.1017810 Search in Google Scholar

Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 11, 141–146, 2008.10.1007/s11102-008-0107-5 Search in Google Scholar

Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr 36, 42–45, 2013.10.18773/austprescr.2013.021 Search in Google Scholar

Convens C, Verhelst J, Mahler C. Painful gynaecomastia during omeprazole therapy. Lancet 338, 1153, 1991.10.1016/0140-6736(91)92018-W Search in Google Scholar

Coulson M, Gibson GG, Plant N, Hammond T, Graham M. Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: Implications for Leydig cell carcinogenesis. Toxicol Appl Pharmacol 192, 154–163, 2003.10.1016/S0041-008X(03)00275-8 Search in Google Scholar

Dammann HG, von zur Muhlen A, Balks HJ, Damaschke A, Steinhoff J, Hennig U, Schwarz JA, Fuchs W. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 7, 191–196, 1993.10.1111/j.1365-2036.1993.tb00089.x8485272 Search in Google Scholar

Dammann HG, Bethke T, Burkhardt F, Wolf N, Khalil H, Luehmann R. Effects of pantoprazole on endocrine function in healthy male volunteers. Aliment Pharmacol Ther 8, 549–554, 1994.10.1111/j.1365-2036.1994.tb00329.x7865648 Search in Google Scholar

Dammann HG, Burkhardt F, Wolf N. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers. Aliment Pharmacol Ther 13, 1195–1203, 1999.10.1046/j.1365-2036.1999.00545.x10468701 Search in Google Scholar

Daniels IR, Layer GT. How should gynaecomastia be managed? ANZ J Surg 73, 213–216, 2003.10.1046/j.1445-1433.2002.02584.x Search in Google Scholar

Drago F, Pellegrini-Quarantotti B, Scapagnini U, Gessa GL. Short-term endogenous hyperprolactinaemia and sexual behavior of male rats. Physiol Behav 26, 277–279, 1981.10.1016/0031-9384(81)90023-8 Search in Google Scholar

Duwicquet F, Gras-Champel V, Masmoudi K. Hyperprolactinemia with galactorrhea induced by lansoprazole: A case report. Therapie 72, 691–693, 2017.10.1016/j.therap.2017.06.00229061292 Search in Google Scholar

Eudravigilance. European database of suspected adverse drug reaction reports–Search [Open Access to the Eudra-Vigilance]. European Database of Suspected Adverse Drug Reaction Reports – Search, 2021. Search in Google Scholar

Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol 32, 1295–1302, 2017.10.1111/jgh.1373728092694 Search in Google Scholar

Ferreira M, Mesquita M, Quaresma M, Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 53, 56–61, 2008.10.1111/j.1365-2559.2008.03059.x18613925 Search in Google Scholar

Galdiero M, Pivonello R, Grasso LFS, Cozzolino A, Colao A. Growth hormone, prolactin, and sexuality. J Endocrinol Invest 35, 782–794, 2012.10.1007/BF0334580528726215 Search in Google Scholar

Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. Brit Med J 308, 503–506, 1994.10.1136/bmj.308.6927.50325427838136667 Search in Google Scholar

Haddad P, Wieck A. Antidepressant-induced hyperprolactinaemia. J Psychopharmacol 14, A28, 2000. Search in Google Scholar

Hall TR, Harvey S, Chadwick A. Mechanism of serotonin effects on prolactin and growth hormone secretion in domestic fowl. Acta Endocrinol 104, 266–271, 1983.10.1530/acta.0.10402666227192 Search in Google Scholar

Hansen KA. Hyperprolactinemia and the dopamine receptor. US Endocr Dis 1, 2–5, 2006.10.17925/USE.2006.00.1.2b Search in Google Scholar

Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy 39, 443–453, 2019.10.1002/phar.2235645374530779194 Search in Google Scholar

He B, Carleton B, Etminan M. Risk of gynecomastia with users of proton pump inhibitors. Pharmacotherapy 39, 614–618, 2019.10.1002/phar.224530865318 Search in Google Scholar

Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: Evidence and clinical implications. Ther Adv Drug Saf 4, 125–133, 2013.10.1177/2042098613482484411086325083257 Search in Google Scholar

Holt RI. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 22, 28–37, 2008.10.1177/026988110708795118477618 Search in Google Scholar

Howden C, Beastall G, Reid J. An investigation into the effects of omeprazole on renal tubular function and endocrine function in man. Scand J Gastroenterol 21, 169–170, 1986.10.3109/00365528609090932 Search in Google Scholar

Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc 60, 689–690, 2010. Search in Google Scholar

Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 10, 1‒13, 2018.10.1177/2042098618809927646333431019676 Search in Google Scholar

Kadioglu P, Yalin AS, Tiryakioglu O, Gazioglu N, Oral G, Sanli O, Onem K, Kadioglu A. Sexual dysfunction in women with hyperprolactinemia: A pilot study report. J Urol 174, 1921–1925, 2005.10.1097/01.ju.0000176456.50491.5116217346 Search in Google Scholar

Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psych 69, 385–391, 2008.10.4088/JCP.v69n030718278991 Search in Google Scholar

Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 33, 711–717, 2008.10.1016/j.psyneuen.2008.02.00818395353 Search in Google Scholar

Knigge UP. Histaminergic regulation of prolactin secretion. Dan Med Bull 37, 109–124, 1990. Search in Google Scholar

Krysiak R, Szkrobka W, Okopien B. The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia. Pharmacol Rep 70, 227–232, 2018.10.1016/j.pharep.2017.10.00829475005 Search in Google Scholar

La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 3, 929–951, 2007. Search in Google Scholar

Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. Brit Med J 305, 451–452, 1992.10.1136/bmj.305.6851.45118825631392958 Search in Google Scholar

Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 44, 1085–1090, 1999. Search in Google Scholar

Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol 98, 81–88, 1991.10.1055/s-0029-12111041778235 Search in Google Scholar

MacGilchrist AJ, Howden CW, Kenyon CJ, Beastall GH, Reid JL. The effects of omeprazole on endocrine function in man. Eur J Clin Pharmacol 32, 423–425, 1987.10.1007/BF005439803609120 Search in Google Scholar

Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med 10 661–677, 2013.10.1111/j.1743-6109.2012.02735.x22524444 Search in Google Scholar

Mah PM, Webster J. Hyperprolactinemia: Etiology, diagnosis, and management. Sem Reprod Med 20, 365–374, 2002.10.1055/s-2002-3670912536359 Search in Google Scholar

Meikle AW, Sanders SW, Tolman KG, Jennings DE, Karol MD, Gary L. Ringham GL. Effect of lansoprazole on male hormone function. Drug Invest 8, 191–202, 1994.10.1007/BF03258478 Search in Google Scholar

Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Repr Sci 6, 168–175, 2013.10.4103/0974-1208.121400385387224347930 Search in Google Scholar

Marken P, Haykal R, Fisher J. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11, 851–856, 1992. Search in Google Scholar

Mat Saad AZ, Collins N, Lobo M, O’Connor HJ. Proton pump inhibitors: A survey of prescribing in an Irish general hospital. Int J Clin Pract 59, 31–34, 2005.10.1111/j.1742-1241.2004.00298.x15707461 Search in Google Scholar

Mathew B, Mathew J, Kiran Y, Geethu C, Varghese S, Ivan T. Study and assessment of appropriateness in the usage of proton pump inhibitors in a tertiary care teaching hospital in South India. Indo Am J Pharm Res 5, 2848–2856, 2015. Search in Google Scholar

Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 32, 618–622, 2014.10.1016/j.ajem.2014.03.01924721025 Search in Google Scholar

Meikle AW, Sanders SW, Tolman KG, Jennings DE, Karol MD, Gary L, Ringham GL. Effect of Lansoprazole on male hormone function. Drug Invest 8, 191–202, 1994.10.1007/BF03258478 Search in Google Scholar

Milenkovic L, D’Angelo G, Kelly PA, Weiner RI. Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT1 neuronal cell lines through prolactin receptors. Proc Nat Acad Sci U.S.A. 91, 1244–1247, 1994.10.1073/pnas.91.4.1244431338108395 Search in Google Scholar

Mohanty BK, Choudhury AK, Baliarsinha AK. Study of clinical presentations of patients with hyperprolactinaemia visiting and therapy care hospital. J Evid Based Med Healthcare, 3, 2745–274, 2016.10.18410/jebmh/2016/601 Search in Google Scholar

Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 80, 1050–1057, 2005.10.4065/80.8.1050 Search in Google Scholar

Muller P, Seitz HK, Simon B, Dammann HG, Feurle G, Huefner M, Lichtwald K, Schmidt-Gayk H. [4 weeks’ administration of omeprazole: Effect on acid behavior and basal hormone levels]. Z Gastroenterol 22, 236‒240, 1984. Search in Google Scholar

Naqvi S, Saqib S, Khan W, Syed I. Rising use of Proton Pump inhibitors: A Karachi perspective. Sci Int (Lahore), 26, 1941–1944, 2014. Search in Google Scholar

Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 95, 3118–3122, 2000.10.1016/S0002-9270(00)02052-9 Search in Google Scholar

Naunton M, Peterson G, Deeks L, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 43, 65–72, 2018.10.1111/jcpt.1261328895169 Search in Google Scholar

Omu AE, Al-Bader AA, Dashti H, Oriowo MA. Magnesium in human semen: Possible role in premature ejaculation. Arch Androl 46, 59–66, 2001.10.1080/0148501015021116411204619 Search in Google Scholar

Ortiz-Guerrero G, Amador-Munoz D, Calderon-Ospina CA, Lopez-Fuentes D, Nava Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast 2018, 5257285, 2018.10.1155/2018/5257285588398429755512 Search in Google Scholar

Paick JS, Yang JH, Kim SW, Ku JH. The role of prolactin levels in the sexual activity of married men with erectile dysfunction. BJU Int 98, 1269–1273, 2006.10.1111/j.1464-410X.2006.06507.x17125484 Search in Google Scholar

Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM, REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Int Med 22, 205–210, 2011.10.1016/j.ejim.2010.11.00921402255 Search in Google Scholar

Patrascu OM, Chopra D, Dwivedi S. Galactorrhoea: Report of two cases. Maedica 10, 136–139, 2015. Search in Google Scholar

Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28, 421–453, 2014.10.1007/s40263-014-0157-3402298824677189 Search in Google Scholar

Pipaliya N, Solanke D, Rathi C, Patel R, Ingle M, Sawant P. Esomeprazole induced galactorrhea: A novel side effect. Clin J Gastroenterol 9, 13–16, 2016.10.1007/s12328-015-0622-726661629 Search in Google Scholar

Prieto OI, Alia EM, Gonzalez AR. Galactorrea inducida por lansoprazol. Atencion Primaria 34, 325, 2004.10.1016/S0212-6567(04)79506-2 Search in Google Scholar

Prikis M, MacDougall J, Narasimhadevara N. Proton pump inhibitor-induced galactorrhea in a kidney transplant recipient: a friend or foe? Case Rep Transplant 8108730, 2020.10.1155/2020/8108730725407932566351 Search in Google Scholar

Rajgadhi H, Makwana H, Malhotra S, Patel P. Levosulpiride and esomeprazole induced hyperprolactinemia case report of drug induced hyperprolactinemia. Natl J Integr Res Med 8, 158–160, 2017. Search in Google Scholar

Rosenshein B, Flockhart DA, Ho H. Induction of testosterone metabolism by esomeprazole in a CYP2C19^*2 heterozygote. Am J Med SCi 327, 289–293, 2004.10.1097/00000441-200405000-0003215166754 Search in Google Scholar

Sachs G, Shin JM, Howden CW. Review article: The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23, 2–8, 2006.10.1111/j.1365-2036.2006.02943.x16700898 Search in Google Scholar

Sansone A, Romanelli F, Sansone M, Lenzi A, Di Luigi L. Gynecomastia and hormones. Endocrine 55, 37–44, 2017.10.1007/s12020-016-0975-927145756 Search in Google Scholar

Sartorio A, Pizzocaro A, Liberati D, De Nicolao G, Veldhuis JD, Faglia G. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: Deconvolution-based assessment. Clin Endocrinol 52, 703–712, 2000.10.1046/j.1365-2265.2000.00987.x28796358 Search in Google Scholar

Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthr Res Ther 15, 1–6, 2013.10.1186/ar4177389101024267413 Search in Google Scholar

Schnell SA, You S, El Halawani ME. D1 and D2 Dopamine Receptor Messenger Ribonucleic Acid in Brain and Pituitary during the Reproductive Cycle of the Turkey Hen1. Biol Reprod 60, 1378–1383, 1999.10.1095/biolreprod60.6.137810330096 Search in Google Scholar

Shafi S, Soomro R, Abbas SZ. Proton pump inhibitors–overprescribed in a rural community. Pak J Med Sci 27, 300–302, 2011. Search in Google Scholar

Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104, 2009.10.1007/s11102-008-0097-318338266 Search in Google Scholar

Shin JM, Sachs, G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10, 528–534, 2008.10.1007/s11894-008-0098-4285523719006606 Search in Google Scholar

Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol, 22, 109–114, 2002.10.1097/00004714-200204000-00002 Search in Google Scholar

Snowdon CT, Ziegler TE. Variation in prolactin is related to variation in sexual behavior and contact affiliation. PloS One 10, e0120650, 2015.10.1371/journal.pone.0120650 Search in Google Scholar

Soran H, Wu FCW. Endocrine causes of erectile dysfunction. Int J Androl 28, 28–34, 2005.10.1111/j.1365-2605.2005.00596.x Search in Google Scholar

Stobie KM, Shin SH. Serotonin stimulates prolactin secretion in the hypophysectomized adenohypophyseal grafted rat. Acta Endocrinol 102, 511–516, 1983.10.1530/acta.0.1020511 Search in Google Scholar

Thanoon IAJ, Mahmood AQ. Effect of omeprazole on reproductive hormonal levels and sexual function in male patients with peptic ulcer disease. Al-Qadisiyah Med J 7, 190–198, 2011. Tian C. Can vitamin B12 deficiency cause infertility? Firstcry Parenting 2018. Search in Google Scholar

Toprak O, Sari Y, Koc A, Sari E, Kirik A. The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: A prospective cross-sectional study. Clin Interv Aging, 12, 437–444, 2017.10.2147/CIA.S129377 Search in Google Scholar

Touitou Y, Haus E. Ageing and the endocrine circadian system. NeuroImmune Biology 4, 165–193, 2004.10.1016/S1567-7443(04)80013-9 Search in Google Scholar

Urbas R, Huntington W, Napoleon L, Wong P, Mullin J. Malabsorption-related issues associated with chronic proton pump inhibitor usage. Austin J Nutr Metab 3, 1041, 2016. Search in Google Scholar

van Vliet EP, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, Siersema PD. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol 20, 608–612, 2008.10.1097/MEG.0b013e3282f52f9518679061 Search in Google Scholar

Van Vugt DA, Meites J. Influence of endogenous opiates on anterior pituitary function. Fed Proc 8, 2533–2538, 1980. Search in Google Scholar

Verhelst J, Abs R. Hyperprolactinemia. Treat Endocrinol 2, 23–32, 2003.10.2165/00024677-200302010-0000315871552 Search in Google Scholar

VigiAccess. World Health Organization. Open Access to the WHO Global Pharmacovigilance Database. World Health Organization, 2021. Search in Google Scholar

Voicu V, Medvedovici A, Ranetti AE, Radulescu FS. Drug-induced hypo- and hyperprolactinemia: Mechanisms, clinical and therapeutic consequences. Exp Opin Drug Metab Toxicol 9, 955–968, 2013.10.1517/17425255.2013.79128323600946 Search in Google Scholar